In this webinar, leading scientists will focus on how a Direct-to-Biology (D2B) approach can accelerate drug discovery. First, an overview will be given including the benefits of the Direct-to-Biology services approach and the typical workflow using examples of internally-generated data on bifunctional degraders. Following this, a case study applying a D2B drug discovery approach to discover a CNS active GSK3 degrader will be presented along with future perspectives.

By attending this webinar, you will learn about:

• An introduction to the Direct-to-Biology Services for drug discovery
  • Overview of how D2B accelerates drug discovery
  • Highlight the requirement for a high throughput workflow
  • Case studies
  • Highlight the wide range of D2B-compatible bioassays and chemistries
• Discovery of bifunctional molecules for the central nervous system with a direct-to-biology approach